We report an unusual case of Plasmodium vivax malaria that occurred in a 22-year-old ankylosing spondylitis patient after initiating adalimumab therapy. P. falciparum malaria was initially included as a possible differential diagnosis due to hyperparasitemia and similar features in the peripheral blood smear. The patient was successfully treated with conventional therapy for P. vivax malaria.
Introduction
Indigenous malaria was thought to have been eliminated from South Korea until a case reemerged in 1993. Most of the cases have been due to Plasmodium vivax; P. falciparum malaria has not been reported as an indigenous case. Known endemic areas for P. vivax malaria in Korea include some northern regions of Kyunggi province and a sector of the demilitarized zone (DMZ) (1) . The diagnosis of malaria is established using a peripheral blood smear and morphological characteristics of individual parasites are often helpful in confirming the diagnosis. We report a case of P. vivax malaria in a patient receiving adalimumab that had similar blood smear findings as P. falciparum malaria.
Case Report
A 22-year-old male was admitted because of fever and chills.
The patient had been previously diagnosed with ankylosing spondylitis (AS) 1-year previously and adalimumab had been initiated 1-month prior to the current admission. The patient had completed military service 6 months previously in Yeunchun, Kyunggi province, which is an endemic area for P. vivax malaria. After military service, the patient moved back to his hometown, Jeju Island, and did not travel outside the island for the following 6 months. The patient had been in typical health until 7 days prior to the current admission, when subjective fever, chills, fatigue, and malaise developed. peripherally ( Figure 1 ). On the basis of these findings, adalimumab therapy was stopped and chloroquine was begun under the suspicion of malaria. By the second day after treatment the patient became afebrile and parasitemia was improved (parasites per white blood cell: 5 per 100). By the fifth day after treatment, parasitemia disappeared in the peripheral blood smear. Polymerase chain reaction-based molecular analysis showed a positive result for P. vivax. Primaquine was administered for 14 days. After being discharged, the patient had no relapse or adverse event during a 2-year follow-up.
Discussion
We report a case of P. vivax malaria that presented with atypical features in a peripheral blood smear after beginning adalimumab therapy. The blood smear showed marked parasitemia and multiple ring forms located peripherally in the RBCs. These features are commonly seen in the blood smear of P. falciparum malaria, whereas they are rarely evident in P. vivax malaria (2). However, several clues pointed the diagnosis towards P. vivax malaria. First, the patient was stationed in a P. vivax-endemic area during military service and had not traveled abroad before service. Second, after military service the patient returned to Jeju Island, a non-endemic area for malaria. Thirdly, the patient had never received a blood transfusion. Furthermore, P. falciparum malaria has never been reported in South Korea. Therefore, it was reasonable to believe that the P. vivax parasites had infected the subject during the military service, remained dormant as hypnozoites in the liver, and reactivated after a latent period of more than 6 months. Interestingly, it was only a month after the subject commenced adalimumab therapy that the symptoms manifested. These two events may have occurred by chance, or the adalimumab treatment may have triggered reactivation of P. vivax malaria.
Adalimumab is a tumor necrosis factor-alpha (TNF-α) inhibitor that is now broadly used in patients with autoimmune diseases like rheumatoid arthritis or ankylosing spondylitis.
Systematic reviews have reported that TNF-α inhibitors increase the risk of serious infection by 2-4-fold (3).
Furthermore, the risk is particularly relevant to intracellular organisms like tuberculosis, histoplasmosis, and listeriosis be- In our case, the final diagnosis was P. vivax malaria. To our knowledge there has been no report regarding atypical features shown in P. vivax infected patients using a TNF-α inhibitor. 
